Search results
Showing 1141 to 1155 of 1237 results for pain
Digital technologies for managing non-specific low back pain: early value assessment (HTE16)
We have moved health technology evaluation 16 to become HealthTech guidance 712. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Percutaneous coblation of the intervertebral disc for low back pain and sciatica (IPG543)
We have moved interventional procedures guidance 543 to become HealthTech guidance 397. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain (IPG739)
We have moved interventional procedures guidance 739 to become HealthTech guidance 641. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
GaitSmart rehabilitation exercise programme for gait and mobility issues (HTG716)
Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.
View recommendations for TA274Show all sections
Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)
Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.
Evidence-based recommendations on garadacimab (Andembry) for preventing recurrent attacks of hereditary angioedema in people 12 years and over.
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)
NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot
We have moved interventional procedures guidance 545 to become HealthTech guidance 399. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Robot-assisted surgery for soft tissue procedures: early value assessment (HTG742)
Early value assessment (EVA) guidance on robot-assisted surgery for soft tissue procedures.
This guideline covers keeping adults in care homes safe from abuse and neglect. It includes potential indicators of abuse and neglect by individuals or organisations, and covers the safeguarding process from when a concern is first identified through to section 42 safeguarding enquiries. There are recommendations on policy, training, and care home culture, to improve care home staff awareness of safeguarding and ensure people can report concerns when needed.
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.
Evidence-based recommendations on nusinersen (Spinraza) for treating spinal muscular atrophy in children and adults.